Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT06458439
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • High-grade B-cell Lymphoma
  • Lymphoma, Non-Hodgkin
  • Refractory Diffuse Large B-cell Lymphoma
  • Relapsed Diffuse Large B Cell Lymphoma
  • Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Epcoritamab — DRUG
    * C1D1: fixed priming dose of 0.16 mg subcutaneous injection * C1D8: fixed intermediate dose of 0.8 mg subcutaneous injection * C1D15 onward: fixed full dose of 48 mg subcutaneous injection

Study Details

This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.

Key Dates

Start date
Sep 24, 2024
Status verified
May 2026
Primary completion
Oct 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
31 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Epcoritamab
    Study participants will bridging epcoritamab on Cycles 1-3, Days 1, 8, 15, and 22 (once weekly).

Primary Outcome Measure

Occurrence of CAR T cell infusion among subjects who receive epcoritamab and undergo leukapheresis [ Time Frame: Start of epcoritamab to CAR T-cell infusion ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Abramson Cancer Center at the University of PennsylvaniaPhiladelphiaPennsylvania19104
Brittany Koch
[email protected]
215-776-5548
Kaitlin Kennard
[email protected]
Elise Chong, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By research site
Abramson Cancer Center at the University of Pennsylvania· Philadelphia, PA

Related Studies